OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study
Davide Giuseppe Ribaldone, Elisa Tribocco, Chiara Rosso, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 15, pp. 3387-3387
Open Access | Times Cited: 26
Davide Giuseppe Ribaldone, Elisa Tribocco, Chiara Rosso, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 15, pp. 3387-3387
Open Access | Times Cited: 26
Showing 1-25 of 26 citing articles:
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
Hillel P. Cohen, Sohaib Hachaichi, Wolfram Bodenmueller, et al.
BioDrugs (2022) Vol. 36, Iss. 5, pp. 625-637
Open Access | Times Cited: 33
Hillel P. Cohen, Sohaib Hachaichi, Wolfram Bodenmueller, et al.
BioDrugs (2022) Vol. 36, Iss. 5, pp. 625-637
Open Access | Times Cited: 33
Switching Among Biosimilars: A Review of Clinical Evidence
Eleonora Allocati, Brian Godman, Marco Gobbi, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 32
Eleonora Allocati, Brian Godman, Marco Gobbi, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 32
Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching
Hillel P. Cohen, Wolfram Bodenmueller
BioDrugs (2024) Vol. 38, Iss. 3, pp. 331-339
Open Access | Times Cited: 7
Hillel P. Cohen, Wolfram Bodenmueller
BioDrugs (2024) Vol. 38, Iss. 3, pp. 331-339
Open Access | Times Cited: 7
Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort
Beatriz Gros, Nikolas Plevris, Nathan Constantine‐Cooke, et al.
United European Gastroenterology Journal (2023) Vol. 11, Iss. 2, pp. 179-188
Open Access | Times Cited: 14
Beatriz Gros, Nikolas Plevris, Nathan Constantine‐Cooke, et al.
United European Gastroenterology Journal (2023) Vol. 11, Iss. 2, pp. 179-188
Open Access | Times Cited: 14
Clinical use of biologics for Crohn’s disease in adults: lessons learned from real-world studies
Antonio Tursi, Giammarco Mocci, Angelo Del Gaudio, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 3, pp. 171-189
Closed Access | Times Cited: 4
Antonio Tursi, Giammarco Mocci, Angelo Del Gaudio, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 3, pp. 171-189
Closed Access | Times Cited: 4
Anti-TNFα in inflammatory bowel disease: from originators to biosimilars
Zhen Zeng, Hao Lin, Mingshan Jiang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Zhen Zeng, Hao Lin, Mingshan Jiang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease
Marta Vernero, Cristina Bezzio, Davide Giuseppe Ribaldone, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 21, pp. 6839-6839
Open Access | Times Cited: 10
Marta Vernero, Cristina Bezzio, Davide Giuseppe Ribaldone, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 21, pp. 6839-6839
Open Access | Times Cited: 10
[Artículo traducido] Eficacia y seguridad de un adalimumab biosimilar en pacientes con enfermedad inflamatoria intestinal
Jaime E. Poquet-Jornet, Inés Ibáñez-Sala, Teresa Garrigues-Pelufo, et al.
Farmacia Hospitalaria (2025)
Open Access
Jaime E. Poquet-Jornet, Inés Ibáñez-Sala, Teresa Garrigues-Pelufo, et al.
Farmacia Hospitalaria (2025)
Open Access
Biobetters and biosimilars in Inflammatory Bowel Disease
Jacopo Fanizza, Ilaria Faggiani, Mariangela Allocca, et al.
Best Practice & Research Clinical Gastroenterology (2025), pp. 101992-101992
Closed Access
Jacopo Fanizza, Ilaria Faggiani, Mariangela Allocca, et al.
Best Practice & Research Clinical Gastroenterology (2025), pp. 101992-101992
Closed Access
Switching from Adalimumab Reference Product to and Among Adalimumab Biosimilars Outside the USA: Insights for US Clinicians
John Tesser, Aline Charabaty, Adelaide A. Hebert
BioDrugs (2025)
Open Access
John Tesser, Aline Charabaty, Adelaide A. Hebert
BioDrugs (2025)
Open Access
Switch acceptance and persistence of adalimumab biosimilars in IBD patients: a prospective observational study
Gabrielle D’Abbundo, Maria Nachury, Alice Wartski, et al.
Therapeutic Advances in Gastroenterology (2025) Vol. 18
Open Access
Gabrielle D’Abbundo, Maria Nachury, Alice Wartski, et al.
Therapeutic Advances in Gastroenterology (2025) Vol. 18
Open Access
Real‐world experience of multiple switches between adalimumab biosimilars in patients with psoriasis
Ole Krogh‐Jensen, C. Schwarz, Diljit Kaur‐Knudsen, et al.
Journal of the European Academy of Dermatology and Venereology (2025)
Closed Access
Ole Krogh‐Jensen, C. Schwarz, Diljit Kaur‐Knudsen, et al.
Journal of the European Academy of Dermatology and Venereology (2025)
Closed Access
Adalimumab Persistence and Its Biosimilar in Inflammatory Bowel Disease: A Real-World Study
María del Carmen Fernández Cano, Antonio Jesús Fernández-Cano, M M Martín-Rodríguez, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 556-556
Open Access | Times Cited: 3
María del Carmen Fernández Cano, Antonio Jesús Fernández-Cano, M M Martín-Rodríguez, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 556-556
Open Access | Times Cited: 3
Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease – a prospective, multicentre study
Livia Lontai, Lóránt Gönczi, F Balogh, et al.
Digestive and Liver Disease (2022) Vol. 54, Iss. 12, pp. 1639-1645
Open Access | Times Cited: 13
Livia Lontai, Lóránt Gönczi, F Balogh, et al.
Digestive and Liver Disease (2022) Vol. 54, Iss. 12, pp. 1639-1645
Open Access | Times Cited: 13
Preparing for the market entry of adalimumab biosimilars in the US in 2023: A primer for specialty pharmacists
Stefanie Cisek, David Choi, JoAnn Stubbings, et al.
American Journal of Health-System Pharmacy (2023) Vol. 80, Iss. 18, pp. 1223-1233
Closed Access | Times Cited: 5
Stefanie Cisek, David Choi, JoAnn Stubbings, et al.
American Journal of Health-System Pharmacy (2023) Vol. 80, Iss. 18, pp. 1223-1233
Closed Access | Times Cited: 5
An Update on Anti-TNF Biosimilar Switching—Real-World Clinical Effectiveness and Safety
Susanna Meade, Elizabeth Squirell, T T Hoang, et al.
Journal of the Canadian Association of Gastroenterology (2023) Vol. 7, Iss. 1, pp. 30-45
Open Access | Times Cited: 5
Susanna Meade, Elizabeth Squirell, T T Hoang, et al.
Journal of the Canadian Association of Gastroenterology (2023) Vol. 7, Iss. 1, pp. 30-45
Open Access | Times Cited: 5
Current evidence on the use of the adalimumab biosimilar SB5 (ImraldiTM): a multidisciplinary perspective
Javier P. Gisbert, Karl Gaffney, David Young, et al.
Expert Opinion on Biological Therapy (2021) Vol. 22, Iss. 2, pp. 109-121
Open Access | Times Cited: 12
Javier P. Gisbert, Karl Gaffney, David Young, et al.
Expert Opinion on Biological Therapy (2021) Vol. 22, Iss. 2, pp. 109-121
Open Access | Times Cited: 12
Switching from SB2 to PF-06438179/GP1111 and back in inflammatory bowel disease: “The Superswitchers”
Fabio Salvatore Macaluso, Angelo Casà, Sara Renna, et al.
Digestive and Liver Disease (2023) Vol. 55, Iss. 3, pp. 424-425
Closed Access | Times Cited: 4
Fabio Salvatore Macaluso, Angelo Casà, Sara Renna, et al.
Digestive and Liver Disease (2023) Vol. 55, Iss. 3, pp. 424-425
Closed Access | Times Cited: 4
Adalimumab and ABP 501 in the Treatment of a Large Cohort of Patients with Inflammatory Arthritis: A Real Life Retrospective Analysis
Andrea Becciolini, Simone Parisi, Rosalba Caccavale, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 3, pp. 335-335
Open Access | Times Cited: 7
Andrea Becciolini, Simone Parisi, Rosalba Caccavale, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 3, pp. 335-335
Open Access | Times Cited: 7
Critical appraisal and future outlook on anti-inflammatory biosimilar use in chronic immune-mediated inflammatory diseases
Stefan Schreiber, L. Puig, João Gonçalves, et al.
Seminars in Arthritis and Rheumatism (2022) Vol. 55, pp. 152023-152023
Open Access | Times Cited: 7
Stefan Schreiber, L. Puig, João Gonçalves, et al.
Seminars in Arthritis and Rheumatism (2022) Vol. 55, pp. 152023-152023
Open Access | Times Cited: 7
Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018
Yifei Liu, Martha Skup, Min Yang, et al.
Advances in Therapy (2022) Vol. 39, Iss. 8, pp. 3711-3734
Open Access | Times Cited: 7
Yifei Liu, Martha Skup, Min Yang, et al.
Advances in Therapy (2022) Vol. 39, Iss. 8, pp. 3711-3734
Open Access | Times Cited: 7
Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases
Uta Kiltz, Styliani Tsiami, Xenofon Baraliakos, et al.
Therapeutic Advances in Musculoskeletal Disease (2022) Vol. 14
Open Access | Times Cited: 6
Uta Kiltz, Styliani Tsiami, Xenofon Baraliakos, et al.
Therapeutic Advances in Musculoskeletal Disease (2022) Vol. 14
Open Access | Times Cited: 6
Safety and Effectiveness of Multiple Switching Between Originators and Biosimilars: Literature Review and Status Report on Interchangeability
Ruggero Lasala, Paolo Abrate, Andrea Zovi, et al.
Therapeutic Innovation & Regulatory Science (2022) Vol. 57, Iss. 2, pp. 352-364
Closed Access | Times Cited: 5
Ruggero Lasala, Paolo Abrate, Andrea Zovi, et al.
Therapeutic Innovation & Regulatory Science (2022) Vol. 57, Iss. 2, pp. 352-364
Closed Access | Times Cited: 5
Effectiveness and safety of adalimumab biosimilar in patients with inflammatory bowel disease
Jaime E. Poquet-Jornet, Inés Ibáñez-Sala, Teresa Garrigues-Pelufo, et al.
Farmacia Hospitalaria (2024)
Open Access
Jaime E. Poquet-Jornet, Inés Ibáñez-Sala, Teresa Garrigues-Pelufo, et al.
Farmacia Hospitalaria (2024)
Open Access
Biologics in Focus: A Comprehensive Review of Current Biological and Small Molecules Therapies for Crohn’s Disease in the United Arab Emirates (UAE)
Laith Alrubaiy, Louise Christine Pitsillides, T O'Connor, et al.
Gastrointestinal Disorders (2024) Vol. 6, Iss. 3, pp. 644-660
Open Access
Laith Alrubaiy, Louise Christine Pitsillides, T O'Connor, et al.
Gastrointestinal Disorders (2024) Vol. 6, Iss. 3, pp. 644-660
Open Access
